Featured Research

from universities, journals, and other organizations

Protein Predicts Gleevec Resistance In Gastrointestinal Tumors

Date:
May 15, 2008
Source:
Fox Chase Cancer Center
Summary:
Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors could indicate that the patient would be less responsive to Gleevec. Preliminary studies have shown that GIST cells, especially Gleevec-resistant cells, might respond well to agents in development for treatment-resistant breast cancer, which is also marked by excessive IGF-1R production. IGF-1R could also serve as a marker to identify Gleevec-resistant patients before therapy begins, when alternative treatments would be most effective.

Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia. Preliminary studies have shown that GIST cells, especially Gleevec-resistant cells, might respond well to agents in development for treatment-resistant breast cancer, a form of breast cancer also marked by excessive production of the IGF-1R protein. IGF-1R could also serve as a marker to identify this subset of GIST patients before therapy begins, when alternative treatments would be most effective, the researcher says.

"A small percentage of adult gastrointestinal stromal tumors -- and most pediatric cases --are often less responsive to Gleevec," says Godwin, Director of Fox Chase's Clinical Molecular Genetics Laboratory. "We have found that tumors in many of these cases coincide with an overabundance of the IGF-1R protein."

In most occurrences, GISTs develop through a mutation in the genes c-KIT or PDGFR±, both of which are targets of Gleevec. GISTs without those mutations, known as "wild type," as well as pediatric GISTs, do not often respond well to treatment with Gleevec.

The Fox Chase researchers found that, when compared to mutant GISTs, the DNA of wild type and pediatric GISTs exhibited more copies of the IGF1R gene. These tumors also produced many more copies of the IGF-1R protein, which serves to promote cell survival, proliferation and growth in normal cells. In tumors, an excess of IGF-1R allows cancer cells to grow out of control, breaking the normal control mechanisms that are an inherent part of cell function. In the laboratory, the researchers found that drugs that decrease IGF-1R activity induced the death of tumor cells.

According to Godwin and his colleagues, their studies are the first to reveal that the development of wild type GISTs could be related to abnormal expression of IGF-1R.

"IGF-1R overproduction seems to be a common factor in a number of different cancers, and there are several IGF-1R-targeted therapeutic agents in development and in clinical trials that might also be effective against GISTs," Godwin says. "As is often the case with targeted therapies, we need to find the right patient for the drug as much as we need to find the right drug for the disease."

Godwin and his colleagues will soon publish the full results of their studies and have begun investigating the possibility of testing for IGF-1R in clinical trials at Fox Chase.

Godwin presents his findings at the 2008 Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3 in Chicago.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Protein Predicts Gleevec Resistance In Gastrointestinal Tumors." ScienceDaily. ScienceDaily, 15 May 2008. <www.sciencedaily.com/releases/2008/05/080515215858.htm>.
Fox Chase Cancer Center. (2008, May 15). Protein Predicts Gleevec Resistance In Gastrointestinal Tumors. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/05/080515215858.htm
Fox Chase Cancer Center. "Protein Predicts Gleevec Resistance In Gastrointestinal Tumors." ScienceDaily. www.sciencedaily.com/releases/2008/05/080515215858.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) — The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) — Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins